MI:RNA
Latest round
- Series A
Last raised
- Jul 2024
Total raised
- $4M
Investors
- 6
About MI:RNA
Based in the UK, MI:RNA Ltd. specializes in veterinary diagnostics, focusing on innovative technologies for early detection of heart disease and other conditions in animals. MI:RNA Ltd. is dedicated to providing advanced diagnostic solutions for veterinary practices. Founded in 2019 by Eve Hanks who is also the CEO, in Edinburgh, UK, the company has successfully completed three deals to date. Recently, In December 2025, MI:RNA Ltd.vc, NovaQuest Capital Management, Scottish Enterprise, Kyoritsu Holdings Corporation, Veterinary Angel Network, Animal Health Angels, Equity Gap and Gabriel Investments Ltd. MI:RNA Diagnostics specializes in veterinary diagnostics, focusing on innovative technologies to detect early-stage heart disease and other conditions in companion and production animals. Their flagship product utilizes serum biomarkers and AI modeling to provide accurate diagnostics, enabling veterinarians to enhance disease monitoring and treatment response for pets, specifically targeting cardiac health in cats and dogs. Additionally, the company is engaged in research related to Johne’s disease screening in production animals, aimed at reducing animal suffering, lowering farmer costs, and contributing to environmental sustainability. MI:RNA's services cater to veterinary practices and agricultural businesses across Europe and North America, providing a comprehensive diagnostic platform that stands to revolutionize animal healthcare by offering veterinarians valuable tools to improve patient outcomes. MI:RNA Diagnostics operates on a business-to-business model, primarily serving veterinary practices and agricultural enterprises. Revenue generation is largely driven through the provision of diagnostic services and products, where veterinary practices may incorporate MI:RNA's testing capabilities into their service offerings. Transactions typically involve direct sales agreements, where veterinary clinics pay for diagnostic tests on a per-use basis or potentially through subscription models that provide ongoing access to the company's diagnostic technology. MI:RNA’s products include proprietary diagnostic tests tailored specifically for different animal health issues, enhancing their value proposition in the marketplace. MI:RNA Ltd. plans to support expansion of its veterinary diagnostics platform, including scaling commercial activities, increasing partnerships with laboratory networks across different regions, and continuing development and validation of its biomarker-based diagnostic models for broader deployment.
Who invested in MI:RNA
6 investors across 1 round
See all investors in MI:RNA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 1, 2024
Amount
$4M
Investors
Questions about MI:RNA
Who invested in MI:RNA?
MI:RNA has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MI:RNA raised?
MI:RNA has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did MI:RNA last raise money?
MI:RNA's most recent round on record is a Series A, in Jul 2024.
What does MI:RNA do?
MI:RNA is a healthcare company.
Where is MI:RNA headquartered?
MI:RNA is headquartered in Edinburgh, UK.
Which VCs invest in companies like MI:RNA?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at MI:RNA's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like MI:RNA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.